Interactions between uncoupling protein 2 gene polymorphisms, obesity and alcohol intake on liver function: a large

Karani S Vimaleswaran1, Alana Cavadino1, Niek Verweij2

  • 1Hugh Sinclair Unit of Human NutritionDepartment of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Whiteknights, PO Box 226, Reading RG6 6AP, UKPopulationPolicy and Practice, UCL Institute of Child Health, London, UKWolfson Institute of Preventive MedicineCentre for Environmental and Preventive Medicine, Queen Mary University of London, London, UK, Departments of CardiologyEpidemiologyUniversity Medical Center Groningen, University of Groningen, Groningen, The NetherlandsUnit of Primary CareOulu University Hospital, Oulu, FinlandFaculty of MedicineCenter for Life Course EpidemiologyDepartment of PsychiatryCenter for Clinical Neuroscience, University of Oulu, Oulu, FinlandDepartment of PsychiatryMedical Research Center, University Hospital of Oulu, Oulu, FinlandDepartment of Epidemiology and BiostatisticsImperial College London, MRC-PHE Centre for Environment and Health, London, UKDepartment of PsychiatryLeiden University Medical Center, Leiden, The NetherlandsDepartment of PsychiatryEMGO Institute of Health and Care Research, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The NetherlandsBiocenter OuluUniversity of Oulu, Oulu, FinlandDepartment of GeneticsUniversity Medical Center Groningen, University of Groningen, Groningen, The NetherlandsICIN - Netherlands Heart InstituteDurrer Center for Cardiogenetic Research, Utrecht, The NetherlandsBarts and The London School of Medicine and DentistryQueen Mary University of London, Blizard Institute, Newark Street, London, UKCentre for Population Health ResearchSchool of Health Science and Sansom Institute of Health Research, University of South Australia, Adelaide, South Australia, AustraliaSouth Australian Health and Medical Research InstituteAdelaide, South Australia, Australia Hugh Sinclair Unit of Human NutritionDepartment of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Whiteknights, PO Box 226, Readin

Summary

Uncoupling protein 2 (UCP2) gene variations do not appear to influence liver enzymes with alcohol intake. However, UCP2 gene polymorphisms interact with body fat, not alcohol, to affect liver enzyme levels.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
282
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
113
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
381